Between 1908 and 1925, William Arbuthnot Lane, a celebrated surgeon at Guy’s Hospital in London, removed all or part of the colon from hundreds of patients, most of them suffering chiefly from constipation. Lane thought the colon was essentially useless and that stagnant stool poisoned the blood, a theory called autointoxication, and he called constipation the cause of all the chronic diseases of civilization. Across the Atlantic, John Harvey Kellogg built the cornflake to put fiber into an American diet he believed was headed for an epidemic of intestinal stasis, and he warned that anything under three bowel movements a day risked putrefaction. The toxins were never there. What outlived the theory was the market it revealed, in which a common, miserable and mostly benign complaint pays whoever sells the most confident fix.
A century on, two expert panels have finally written down what the evidence supports, and the results show that market is still with us. In October 2025, a King’s College London team led by Eirini Dimidi published the first evidence-based dietary guidelines for adults with chronic constipation, endorsed by the British Dietetic Association. After working through more than 75 clinical trials, the panel issued 59 recommendations naming kiwifruit, rye bread, high-mineral water, psyllium, certain probiotic strains and magnesium oxide. Two years earlier, the American College of Gastroenterology and the American Gastroenterological Association had issued a joint drug guideline whose strongest endorsements went to cheap generics and also to three prescription agents, one of which now sells more than a billion dollars a year.
The fruit bowl gets a citation
What fell short in the British review is as telling as what made it. The generic advice to “eat more fiber,” which almost every patient hears first, did not clear the bar for strong evidence. “There simply isn’t enough evidence to suggest it actually works in constipation specifically,” Dimidi said, while noting that a high-fiber diet has broader health benefits. Senna supplements, among the oldest remedies on the shelf, also lacked strong evidence. The panel was blunt about the foundation it was building on, rating most of the existing studies as low quality.
The trials behind specific foods are small, though they are at least direct. In an American comparative trial co-authored by University of Michigan gastroenterologist William Chey, 79 adults with chronic constipation were partially randomized to two green kiwifruit a day, 100 grams of prunes a day, or 12 grams of psyllium for four weeks. Response rates were similar across all three, and kiwifruit caused the fewest side effects and the least dissatisfaction. In Japan, a double-blind trial of 84 adults gave 54 grams of prune juice a day against a matched placebo for eight weeks. Hard, lumpy stools fell and normal ones rose without any increase in loose stools, and nobody reported an adverse event or showed abnormal liver or kidney tests.
The fruit has backers too. MIKI Corporation partly funded the Japanese study, two of its authors work there, and other authors received grants from the company. The incentives differ in size. A prune-juice maker cannot charge hundreds of dollars a month or make a patient wait on a prior-authorization form, and it does not get a strong recommendation from a gastroenterology society.
Who wrote the drug recommendations
The 2023 ACG-AGA guideline deserves credit for one thing first. Its strong recommendations include polyethylene glycol and sodium picosulfate, both inexpensive, and it gave senna, magnesium oxide, fiber and lactulose conditional recommendations, the first time senna and magnesium oxide had appeared in a U.S. society guideline. The strong list also includes linaclotide, plecanatide and prucalopride, for patients who don’t respond to over-the-counter options. The authors acknowledged that some of these drugs exist only as brand-name products because no generic is available, and that prior authorization may be required.
Then there are the disclosures. Lin Chang listed scientific advisory board roles with Ardelyx, Ironwood and others, speaking for Ironwood, and research support from Ironwood, among other companies. Chey listed consulting for AbbVie, Ardelyx, Ironwood, Takeda and others, plus patents and stock options, including options in a company called Kiwi Bioscience. Both Chang and Chey reported financial relationships with Ironwood, which shares the U.S. profits on linaclotide, sold as Linzess, equally with AbbVie.
That arrangement is lucrative. Ironwood reported Linzess U.S. net sales of $282 million in the second quarter of 2026 and raised its full-year guidance to between $1.15 billion and $1.20 billion. None of this shows the recommendation was wrong, because linaclotide has trial evidence of its own. It does mean the doctors grading the brand-name drugs included doctors paid by the brand, a fact patients can reasonably keep in mind when the prescription pad comes out.
The constipation the medicine cabinet makes
Both guidelines are about relief. The question neither panel was asked is how much chronic constipation comes from treating something else, and the answer starts with the chemistry of the gut wall. The muscles that push stool along the colon respond largely to acetylcholine, the same messenger that bladder antispasmodics, older antihistamines, some antidepressants and many other drugs are designed to block, and those effects add up across a patient’s prescriptions. A 2021 systematic review found 11 studies on the question, and 9 of 11 reported at least one association between anticholinergic burden and constipation. Most of those studies weren’t designed for this purpose, few adjusted for confounders, and none measured fiber, fluid or exercise, so the size of the effect is uncertain even though the direction keeps repeating.
| Measure | Part | Whole |
|---|---|---|
| studies tied anticholinergic burden to constipation | 9 | 11 |
Opioids act on receptors in the gut wall itself, which makes them the clearest example. Somewhere between 40 and 90 percent of opioid users develop constipation at some point, and the industry answered with a second drug for the side effect of the first. AstraZeneca’s Movantik, the first new oral drug of its kind approved for patients without cancer, arrived in 2014 and was marketed with Daiichi Sankyo. An analyst forecast had the treatment market in the U.S. and five European countries growing from nearly $67 million in 2016 to more than $652 million by 2019. That February, in the middle of the opioid epidemic, AstraZeneca sponsored a Super Bowl ad about “OIC,” and White House chief of staff Denis McDonough called for “fewer ads that fuel opioid addiction.” The condition was legitimate, and American opioid prescribing was producing it by the millions.
at some point while taking opioids
- Lower bound
- 40
- Upper bound
- 90
Sleep may belong in the same column, though the evidence there is weaker. In Hefei, China, researchers studied 278 patients with functional constipation and found that the 85 with poor sleep on a standard questionnaire scored 15.72 on a constipation symptom scale against 12.75 for the rest, with lower maximal squeeze pressure on anorectal testing. The design was cross-sectional, with no healthy comparison group, so it shows an association and nothing about which came first.
Keeping the ledger
Taken together, the evidence divides into two columns. Relief has modest but tested support in kiwifruit, prunes and prune juice, psyllium, magnesium oxide, mineral-rich water, rye bread and cheap polyethylene glycol, with the brand-name drugs reserved for patients those measures fail. The other column, what is making the patient worse, holds a likely culprit in opioids, a consistent but loosely measured signal in anticholinergic drugs, and only a plausible one in poor sleep. Lane cut out colons to treat a poison that didn’t exist. A patient on four anticholinergic prescriptions who gets a fifth for constipation, with nobody reviewing the first four, is being treated with the same lack of interest in cause, at a lower surgical cost.
The King’s panel paired its 59 recommendations with 12 research priorities, the list of trials nobody has run yet. Ironwood, meanwhile, has told investors to expect more than $1.15 billion in U.S. Linzess sales this year. Watch whether anyone funds those 12 trials at a fraction of that, and whether the next ACG-AGA revision asks the question this one didn’t, which is what the patient was already taking before the constipation started.
Sources
- King’s College London – British Dietetic Association dietary guidelines for chronic constipation, Dimidi and Whelan (2025)
- Healio – ACG-AGA guideline on pharmacological management of chronic idiopathic constipation, with author disclosures (2023)
- Ironwood Pharmaceuticals – second-quarter 2026 results and Linzess guidance (2026)
- Healthcare – Rodríguez-Ramallo et al., systematic review of anticholinergic burden and constipation (2021)
- American Journal of Gastroenterology – Koyama et al., double-blind RCT of prune juice in chronic constipation (2022)
- Practical Gastroenterology – summary of Chey et al., kiwifruit vs. prunes vs. psyllium trial (2021)
- CNBC – Opioid-induced constipation drugs and market projections (2016)
- Frontiers in Neuroscience – Liu et al., sleep deficiency and anorectal and autonomic function in functional constipation (2022)
- TIME – Elsa Richardson, the history of constipation and autointoxication (2024)